Optimizing osteoporosis care the Roles of FOSAMAX PLUS 5600 and the Importance of Vitamin D
(Rickets) ) 17
D 1919 rickets animal model, dogs feeding with bread and low-fat milk Ineffective by adding yeast (provide vitamin B) adding orange juice (provide vitamin C)
Effective by addition of butterfat and cod-liver oil 1920 Hopkins
fat-soluble factor A (
A)
1922 McCollum observed that heated, oxidized cod-liver oil could not prevent xerophthalmia but could cure rickets in the rats ( D)
D UVB
Ergosterol
7-dehydrocholesterol
Calciferol (vitamin D2)
Cholecalciferol (vitamin D3)
D Sun
U VB
ProD3 PreD3 Vitamin D3
小腸
皮膚
Diet Vitamin D3 Vitamin D2
肝臟 25(OH)D (inactive form
腎臟 小腸 PTH (+)
1,25(OH)2D (active form
(+) Low PO42–
)
25(OH)D=25-hydroxyvitamin D; 1,25(OH)2D=1,25-dihydroxyvitamin D Adapted from Holick MF Osteoporos Int 1998;8(suppl 2):S24–S29.
)
D • 25OHD • long circulating half-life of 15 days • reflects vitamin D produced in the skin as well as that acquired from the diet
• 1,25(OH)2D • short half-life of 15 hours • tightly regulated by parathyroid hormone, calcium, and phosphate, such that it does not decrease significantly until vitamin D deficiency is already well advanced
The serum 25OHD concentration is the best available clinical indicator of vitamin D status
1–4
Definition of 25(OH)D Levels
Inadequacy Deficiency
Insufficiency
Optimal
Serum 25(OH)D, ng/mL 0
10
20
30
40
0
25
50
75
100
Serum 25(OH)D, nmol/L
Serum concentration of 25(OH)D, the main circulating metabolite of vitamin D, is the correct functional indicator of vitamin D status.
Serum 1,25(OH)2D should not be measured routinely, as it is not reflective of vitamin D status.
Vitamin D deficiency <9 ng/mL; vitamin D inadequacy <30 ng/mL 1. Binkley N et al. Endocrinol Metab Clin N Am. 2010;39(2):287–301; 2. Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press; 1997; 3. Friedman PA. In: Brunton LL et al, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill Medical Publishing Division; 2006: 1647–1678; 4. Bikle DD et al. J Clin Endocrinol Metab. 1985;61(5):969–975.
Mechanism of Action: Vitamin D and Bone Metabolism
1–4
Balanced System
Low Levels of Vitamin D
Calcium absorption meets metabolic demands Normal bone mineralization is maintained
Calcium reservoir of bone is depleted to correct for low calcium absorption in gut
Dietary calcium
4
Mobilization of calcium from bone
Gut
1 Vitamin D
Circulation Vitamin D
In vitamin D– deficient state, calcium absorption decreases
2
3
PTH Parathyroid Low calcium causes increase in PTH secretion
Calcium reabsorption
PTH
Renal distal tubule
PTH=parathyroid hormone. 1. Holick MF. Curr Opin Endocrinol Diabetes. 2002;9:87–98; 2. DeLuca HF. Am J Clin Nutr. 2004;80(suppl 1):1689S–1696S; 3. Lips P. Endocr Rev. 2001;22(4):477–501; 4. Holick MF. J Nutr. 2005;135:2739S–2748S.
•The rationale of vit D supplementation •The efficacy of vit D supplementation •How to do it in daily practice
D In a cross-sectional, observational, international study in 2589 postmenopausal women with osteoporosis 90
81.8%
N=2589
Prevalence (%)
80 70
71.4%
63.9%
60
53.4%
57.7%
Latin America 拉丁美洲
Europe 歐洲
60.3%
50 40 30 20 10 0
All 全球
Middle East 中東
Regions
Asia 亞洲
Australia 澳洲
韓國,日本,馬來西亞,泰國
*Vitamin D inadequacy was defined as serum 25(OH)D <30 ng/ml Study Design: Observational, cross-sectional study of 2589 community-dwelling women with osteoporosis from 18 countries to evaluate serum 25(OH)D distribution. Adapted from Lips P et al. Poster presented at ASBMR, Nashville, TN, USA, September 23–27, 2005; Heaney RP Osteoporos Int 2000;11:553–555.
D
Prevalence (%)
N=548
100 90 80 70 60 50 40 30 20 10 0
98.0% 98.9% 92.7% 95.6% 81.0%
68.4%
n Patients >60 years old
hospitalized for nontraumatic fractures n Serum 25(OH)D < 30 ng/ml
in 97.8% n Patients had no vitamin D
supplementation <12
<16
<20
<24
<28
<32
Cutoff points for 25(OH)D concentration (ng/ml) *Vitamin D inadequacy was defined as serum 25(OH)D <30 ng/ml Study Design: Multicenter study of 548 patients in Scotland aged >60 years who were hospitalized with hip fractures to assess the prevalence of vitamin D inadequacy (measured by serum 25[OH]D). Adapted from Gallacher SJ et al Curr Med Res Opin 2005;21:1355â&#x20AC;&#x201C;1361; Heaney RP Osteoporos Int 2000;11:553â&#x20AC;&#x201C;555.
Slide 12
Vit D status and response to treatment in postmenopause osteoporosis Osteoporos Int. 2009 Feb;20(2):239-44.
•The rationale of vit D supplementation •The efficacy of vit D supplementation •How to do it in daily practice
â&#x20AC;&#x153;The treatment effect was also best with calcium doses of 1200 mg or more, or vitamin D doses of 800 IU or more
NOF Update its Recommendations for Calcium and Vitamin D3 Intake in 2007!! 800 - 1,000 I.U. of vitamin D3/day for adults 50 and older
1200 mg of calcium/day for adults 50 and older
National Osteoporosis Foundation March 13, 2007
•The rationale of vit D supplementation •The efficacy of vit D supplementation •How to do it in daily practice
D • • • • • • • •
D
100
8~60 200~800 140~150 8500 10 60000 40 28
D
I.U.
D
D
• Sun Protection Factor SPF • SPF15 15 14
UVB UVB
15
sunscreen with an SPF 15 can reduce synthetic capacity by 98% Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium (2011)
D Aspray TJ, Bowring C, Fraser W, et al: National osteoporosis society vitamin D guideline summary. Age and Ageing 2014; 43: 592â&#x20AC;&#x201C;5.
•
25OHD
•
D
•
D vitamin D3
D hyperparathyroidism
•
25OHD
25OHD • 25OHD<30nmol/l
vitamin D deficiency
• 25OHD
vitamin D insufficiency
30 50nmol/l
• 25OHD 50nmol/l
normal
1–4
Definition of 25(OH)D Levels
Inadequacy Deficiency
Insufficiency
Optimal
Serum 25(OH)D, ng/mL 0
10
20
30
40
0
25
50
75
100
Serum 25(OH)D, nmol/L
Serum concentration of 25(OH)D, the main circulating metabolite of vitamin D, is the correct functional indicator of vitamin D status.
Serum 1,25(OH)2D should not be measured routinely, as it is not reflective of vitamin D status.
Vitamin D deficiency <9 ng/mL; vitamin D inadequacy <30 ng/mL 1. Binkley N et al. Endocrinol Metab Clin N Am. 2010;39(2):287–301; 2. Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press; 1997; 3. Friedman PA. In: Brunton LL et al, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill Medical Publishing Division; 2006: 1647–1678; 4. Bikle DD et al. J Clin Endocrinol Metab. 1985;61(5):969–975.
D 800
( 40 IU
2000IU
g)
100IU vitamin D3
D D 1 g vitamin D3
IU
25OHD level 0.7 ~ 1.1 ng/ml
Vitamin D Supplements in Taiwan: D 400 IU
D
D
GN嚼
$650
(60 t瑞生美ets)
400 IU
$490 (100 t瑞生美ets)
400 IU
$360 (60 t瑞生美ets)
400 IU
$469 (60 t瑞生美ets) $645
Main Concerns : Bisphosphonates •
Osteonecrosis of jaw (ONJ)
•
Gastrointestinal irritation
•
Flu-like syndrome
Main Concerns : Bisphosphonates •
Osteonecrosis of jaw (ONJ)
•
Gastrointestinal irritation
•
Flu-like syndrome
An Open -Label Open-Label Clinical Study of Alendronate Plus Colecalciferol
FOCUS D Open-Label Study
Patients With Low Vitamin D Levels: 25(OH)D <20 ng/mL1,2 Baseline Week 26 Week 52
100 84.2
84.0
Patients, %
80 60 40 20 0
36.9
31.0
(n=257)
8.6a
11.3a
(n=221)
(n=212)
Alendronate 70 mg + Colecalciferol 5600 IU
(n=258)
(n=216)
(n=203)
Referred Care
• Significantly fewer patients with low vitamin D levels with alendronate + colecalciferol FOCUS D=FOsavance vs Standard Care – Use and Study of Vitamin D. aP<0.001 vs referred care at each time point. 1. Ralston SH et al. Calcif Tissue Int. 2011 Apr 11. [Epub ahead of print.]; 2. Reginster YV et al. Poster presented at: European Congress on Osteoporosis and Osteoarthritis; 23–26 March 2011; Valencia, Spain.
FOCUS D Open-Label Study
BMD Changes From Baseline at 12 Months1,2 Alendronate 70 mg + colecalciferol 5600 IU Referred care
LS Mean (95% CI) BMD Change From Baseline, %
8 6
Treatment Difference: 1.01 (P=0.047) 4.92 3.91
4
Treatment Difference: 0.82 (P=0.035) 2.22 1.40
2 0 (n=226)
(n=219)
Lumbar Spine
(n=227)
(n=218)
Total Hip
FOCUS D=FOsavance vs Standard Care â&#x20AC;&#x201C; Use and Study of Vitamin D; BMD=bone mineral density; LS=least square; CI=confidence interval. 1. Ralston SH et al. Calcif Tissue Int. 2011 Apr 11. [Epub ahead of print.]; 2. Reginster YV et al. Poster presented at: European Congress on Osteoporosis and Osteoarthritis; 23â&#x20AC;&#x201C;26 March 2011; Valencia, Spain.
Thanks for your attention !!